CDR Grafting

Abnova’s humanized antibody service starts with mouse monoclonal antibody production via mouse immunization, splenic fusion, hybridoma screening, antibody selection, and isotype determination. The selected mouse monoclonal antibody undergoes variable gene sequencing for the complementarity-determining region (CDR) grafting, and if needed specificity determining residues (SDR) grating, onto the human antibody construct followed by sequence alignment and production. The humanized antibody is then characterized by a series of in vitro and in vivo assays to ensure its biochemical, biophysical, and functional properties. Moreover, the Fc region of the humanized antibody is mutated to minimize antibody-dependent enhancement (ADE) immune response.

See Technology